Below are the comprehensive details of the Speciality Medicines IPO:
Key Dates and Timeline
| Event | Date |
| IPO Open Date | Friday, March 20, 2026 |
| IPO Close Date | Tuesday, March 24, 2026 |
| Basis of Allotment | Wednesday, March 25, 2026 |
| Initiation of Refunds / Unblocking of Funds | Friday, March 27, 2026 |
| Credit of Shares to Demat Account | Friday, March 27, 2026 |
| Listing Date (Tentative) | Monday, March 30, 2026 |
IPO Structure and Pricing
| Parameter | Details |
| Total Issue Size | ₹29.14 Crore |
| Issue Type | Fresh Issue (entirely) |
| Number of Shares | 23,50,000 equity shares |
| Price Band | ₹117 to ₹124 per share |
| Face Value | ₹10 per share |
| Market Lot Size | 1,000 Shares |
| Listing Exchange | BSE SME |
Application Lot Size and Investment (Retail)
To apply for the Speciality Medicines IPO, retail investors must bid for a minimum of 2 lots.
| Application | Lots | Shares | Amount (at upper band) |
| Minimum Application | 2 | 2,000 | ₹2,48,000 |
| Maximum Application | 2 | 2,000 | ₹2,48,000 |
Note: For HNI investors, the minimum application starts at 3 lots (3,000 shares), amounting to ₹3,72,000 at the upper price band.
Objectives of the Issue
The company intends to use the net proceeds from the fresh issue for the following purposes:
- Setting up of a Research and Development (R&D) Center: ~43.72% of proceeds.
- To Meet Working Capital Requirements: ~27.59% of proceeds.
- General Corporate Purposes: ~12.63% of proceeds.
- Product Registration and Development in International Markets: ~10.31% of proceeds.
- Funding for Marketing and Promotional Activities: ~5.72% of proceeds.
Key Financial Metrics (Annualized)
Based on annualized data for the period ended October 31, 2025:
| Financial Metric | Value |
| Total Revenue (Annualized) | ₹62.95 Cr |
| Profit After Tax (PAT, Annualized) | ₹10.37 Cr |
| EBITDA Margin | 17.73% |
| PAT Margin | 16.48% |
| Post-IPO Market Capitalization | ₹108.94 Cr (at upper band) |
| P/E Ratio (Post-IPO) | ~10.49x |
Lead Manager and Registrar
| Role | Entity |
| Book Running Lead Manager | Unistone Capital Private Limited |
| Registrar to the Issue | Skyline Financial Services Private Limited |
